Greer Says India Deal 'Not Imminent' — But an Oct. 18 Tariff Trigger Is Now in Play

Speaking on the sidelines of the G20 Trade Ministers meeting in Milwaukee on Oct. 1, U.S. Trade Representative Jamieson Greer said negotiators had \"truly identified the universe of items that are sticking points\" — but that he \"didn't think there's something imminent.\" The comments came a day after Prime Minister Modi called his phone conversation with President Trump \"productive,\" with Trump offering no details. Greer separately confirmed a \"very constructive\" conversation with Commerce Minister Piyush Goyal and said the two leaders may speak again \"very soon\" to assess progress.

The walk-back matters because markets had been pricing the deal as essentially done. Indian equities, IT services bookings, and pharmaceutical exporter multiples all improved after the Feb. 6 joint statement, which framed a \"reciprocal\"18% US tariff on Indian goods — down from 50% — alongside $500 billion of intended Indian purchases from America. Greer's Oct. 1 reset strips out that timeline without stripping out the friction.

The Feb. 6 framework rested on Executive Order 14257, the IEEPA-based \"reciprocal tariff\" regime. Two weeks after the deal was announced, the U.S. Supreme Court ruled6-3 that IEEPA does not authorize tariffs, and the administration revoked the IEEPA orders the same day. The 18% rate never had durable legal cover. A Section 122 10% replacement took effect Feb. 24 with a 150-day statutory cap, then expired on July 24, 2026 — and Section 301 forced-labor duties of 10% (India) and 12.5% (others) took over that same day across 60 economies.

One trade analyst quoted in Indian media summarized the result bluntly: \"the bargain disappeared for the US\" after the court ruling. With the legal foundation gone, the deal is no longer a matter of fine-tuning an existing tariff schedule — it has to be re-engineered under surviving authorities (Section 301, Section 232, and now the new SRIA). That re-engineering is what Greer is negotiating against.

President Trump signed the Lindsey O. Graham Sanctioning Russia and Iran Act of 2026 (SRIA) on Sept. 18, 2026, authorizing up to 100% additional tariffs on countries that knowingly purchase Russian crude or natural gas. The law gives the President 30 days from enactment — i.e., until Oct. 18 — to raise duties on goods from any country ranking among the top five importers of Russian crude or top five facilitators of sanctions evasion. India is comfortably inside that window. The law does not require tariff action; it authorizes it, with a national-interest waiver and 10-day congressional notice.

India's volume of Russian crude imports is the variable that matters. Imports hit a record 2.82 mbpd in July 2026 (55.9% of crude intake), then fell sharply — to 2.1 mbpd in August and roughly 1.9 mbpd in September, a ~9% month-on-month drop. India is diversifying toward Middle Eastern suppliers (which rose to roughly 3 mbpd in September), but the headline number is still high enough to qualify India under the SRIA's top-five test. The waiver route exists but requires certification that relief is in the national interest — a politically loaded step that no administration will take unilaterally.

India exported $9.47 billion of drugs to the U.S. in FY26, about 30.4% of its $31 billion pharma export total. The U.S. accounts for nearly half of all generic prescriptions filled at American pharmacies — 47% per IQVIA's 2024 study. That structural dependence is exactly why Washington has built the tariff architecture around it.

The Nifty Pharma index's reaction captures this: it fell ~2% across all constituents on July 22 when Trump threatened up to 200% on generics, then outperformed the broader market on Sept. 28 when the specialty-drug waiver landed. Dr. Reddy's — the largest US-listed Indian pharma pure-play — has had a harder FY26: consolidated revenue grew only 3.2% YoY to ₹33,593 crore, gross margin compressed from 58.5% to 52.8%, and Q4 revenue dropped 11.6% YoY, partly driven by lenalidomide pricing pressure and CAR-T asset impairment. That's idiosyncratic margin compression, not tariff exposure — and it sits behind a stock that has already given back about 22% from its 52-week high.

IT services aren't in the goods-tariff fight directly. The pressure point for Infosys, TCS, HCL, and Wipro is North American enterprise demand for IT and consulting — a flow that has been soft for three quarters. TCS reported Q1 FY27 revenue of $7.62 billion (flat QoQ, +2.7% YoY) on July 9, with North America at 48.3% of revenue and banking/financial services at 32.1% — both essentially flat year-over-year. Annualized AI revenue hit $2.6 billion, up 13.6% QoQ, and Q1 total contract value was $9.5 billion including an $800 million deal. The set-up is a stabilizing demand environment with margin holding at 24.0%, but not a re-acceleration.

The deeper problem is structural, not political: US clients are renegotiating contracts toward outcome-based pricing (80% of finance, HR and business services contracts are now priced on outcomes rather than hours), and AI-led productivity is reducing headcount intensity. A trade deal would have provided a sentiment lift — the February rally lifted Nifty IT ~4% over the following month — but it does not change the underlying demand curve. Greer's walk-back removes that sentiment lever but does not change the fundamental setup.

India's AI compute buildout is now genuinely large enough to move macro outcomes. Reliance committed $110 billion to AI infrastructure in February 2026, including a 168 MW data center at Jamnagar for Meta and a multi-gigawatt AI-ready park expected online by end-2026. Adani announced a separate $100 billion commitment to renewable-powered, AI-ready data centers by 2035, with an estimated $250 billion ecosystem impact across server manufacturing, sovereign cloud, and supporting industries. Together, the two groups have earmarked roughly $210 billion for AI infrastructure in India.

The dependency that matters here is on Nvidia GPUs and similar accelerators. India has imported H100/H200-class chips via existing channels, but a formalized bilateral digital-trade track under the February framework — covering \"discriminatory or burdensome practices\" in digital services — would have given Reliance's and Adani's buildouts a clearer regulatory runway for advanced chip imports. Greer's walk-back stalls that runway. Indian policymakers now have to choose between continuing the buildout under existing chip-licensing arrangements (slower, more case-by-case) or pressing for a deal that explicitly clears the path.

Greer's Oct. 1 reset shifted the narrative from \"deal-by-year-end\" to \"deal-when.\" Five catalysts in the next twelve weeks will determine whether the stalemate becomes a formal escalation or a quiet revival.